Please upgrade your browser.
Global cancer charity strives to serve patients through the holiday.
World’s Largest Renal Cancer Charity Strives to Serve Patients Through the Holiday
UV rays in sunlight cause DNA damage and sun exposure is a major risk factor in most skin cancers. A recent study from Harvard suggests that sun exposure may also worsen the number and severity of skin lesions found in tuberous sclerosis patients (Tyburczy et al., 2013)
Cancer Research UK and AstraZeneca sign deal to repurpose asthma drug that could fight kidney cancer
Cancer Research UK and Cancer Research Technology – the charity’s development and commercialisation arm – have reached an agreement with AstraZeneca to take AZD2098, an experimental drug originally designed for asthma, into a clinical trial to treat kidney cancer.
A type of cancer treatment that directs the body's own immune system to fight cancer cells has been named as the "breakthrough of the year" by one of the world's top science journals.
NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it had launched a first in human Phase 1 clinical trial of HyperAcute Renal immunotherapy in patients with metastatic renal cell cancer.
Merck is looking for more collaborations like the one with Glaxo to test how MK-3475 works with other anticancer treatments against a variety of tumor types...
"I had very minor side effects," Bachelor said. "After the last one, I just had a little tiredness for a few days."
The association between the Serine/threonine kinase 15 (STK15) F31I polymorphism (rs2273535) and cancer susceptibility remains controversial. To further investigate this potential relationship, we conducted a comprehensive meta-analysis of 27 published studies involving a total of 19,267 multiple cancer cases and 24,359 controls.
Researchers evaluating immunotherapy approaches for treating metastatic kidney, prostate, bladder cancers
Researchers at the Roswell Park Cancer Institute (RPCI) Center for Immunotherapy are enrolling patients in three different clinical trials of novel immunotherapy approaches for treating genitourinary cancers.
|Powered by NeonCRM|